Hagens Berman Urges Endava Investors to Act Before Class Action Deadline
Investors in Endava plc (NYSE: DAVA) should take note of an important announcement from Hagens Berman Sobol Shapiro LLP, a reputable law firm specializing in plaintiffs' rights and complex litigation. The firm is calling on investors who have suffered substantial losses related to their investment in Endava to act quickly, as there is a significant deadline approaching for a federal securities class action lawsuit.
The lawsuit focuses on alleged discrepancies in the company's financial reporting and internal controls during a crucial class period that extends from September 4, 2025, to September 21, 2026. Investors who acquired American Depositary Shares (ADSs) during this timeline and have faced financial setbacks are eligible to apply as lead plaintiff by no later than November 30, 2026. Speaking directly about this case, Hagens Berman partner Reed Kathrein emphasized the importance of transparency, stating, "We're focused on whether Endava may have misled investors regarding its true financial condition."
The backdrop to the lawsuit stems from a series of troubling revelations that surfaced after the market closed on September 21, 2026. Endava announced that its Audit Committee initiated an internal investigation triggered by issues raised by external auditors involving the company's customer and supplier agreements. This announcement led to the immediate placing of the Chief Financial Officer on administrative leave and the postponement of the filing of the company’s annual financial results for that fiscal year. The consequences were swift and dramatic: Endava's ADSs tumbled over 24%, plummeting to a closing price of $2.11 per share the day following these disclosures, resulting in substantial financial losses for shareholders.
Moreover, further scrutiny revealed that some of the agreements lacked economic substance, which necessitated the restatement of quarterly financial statements throughout fiscal year 2026. As detailed in the complaint, it is alleged that Endava and its leadership assured investors that their financial statements accurately reflected the company’s financial health and that their internal controls were sufficient, claims now under severe scrutiny following these accusations.
Investors are being advised to submit their transaction details to allow Hagens Berman to effectively evaluate their potential claims. Furthermore, those with non-public information regarding Endava should also consider cooperating with the investigation or investigating opportunities under the SEC Whistleblower program, which offers rewards for original information that leads to enforcement actions.
Hagens Berman, with a notable track record, continues to focus on holding corporations accountable for their actions, ensuring that investors' rights are protected in such situations. For those interested in learning more or seeking guidance on how to participate, contacting the firm is crucial. Hagens Berman provides dedicated resources including a specific case page on their website and a direct contact method for inquiries regarding this pressing matter. Time is of the essence for affected investors to make informed decisions before the approaching deadline.
The lawsuit focuses on alleged discrepancies in the company's financial reporting and internal controls during a crucial class period that extends from September 4, 2025, to September 21, 2026. Investors who acquired American Depositary Shares (ADSs) during this timeline and have faced financial setbacks are eligible to apply as lead plaintiff by no later than November 30, 2026. Speaking directly about this case, Hagens Berman partner Reed Kathrein emphasized the importance of transparency, stating, "We're focused on whether Endava may have misled investors regarding its true financial condition."
The backdrop to the lawsuit stems from a series of troubling revelations that surfaced after the market closed on September 21, 2026. Endava announced that its Audit Committee initiated an internal investigation triggered by issues raised by external auditors involving the company's customer and supplier agreements. This announcement led to the immediate placing of the Chief Financial Officer on administrative leave and the postponement of the filing of the company’s annual financial results for that fiscal year. The consequences were swift and dramatic: Endava's ADSs tumbled over 24%, plummeting to a closing price of $2.11 per share the day following these disclosures, resulting in substantial financial losses for shareholders.
Moreover, further scrutiny revealed that some of the agreements lacked economic substance, which necessitated the restatement of quarterly financial statements throughout fiscal year 2026. As detailed in the complaint, it is alleged that Endava and its leadership assured investors that their financial statements accurately reflected the company’s financial health and that their internal controls were sufficient, claims now under severe scrutiny following these accusations.
Investors are being advised to submit their transaction details to allow Hagens Berman to effectively evaluate their potential claims. Furthermore, those with non-public information regarding Endava should also consider cooperating with the investigation or investigating opportunities under the SEC Whistleblower program, which offers rewards for original information that leads to enforcement actions.
Hagens Berman, with a notable track record, continues to focus on holding corporations accountable for their actions, ensuring that investors' rights are protected in such situations. For those interested in learning more or seeking guidance on how to participate, contacting the firm is crucial. Hagens Berman provides dedicated resources including a specific case page on their website and a direct contact method for inquiries regarding this pressing matter. Time is of the essence for affected investors to make informed decisions before the approaching deadline.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.